REGULATORY

Japan PM Mulls Legal Revision on Trial Requirement for Vaccines

April 26, 2021
Japanese Prime Minister Yoshihide Suga said on April 23 that he sees the need for a special measure to accelerate the pathway for rolling out vaccines in emergency situations, such as through a legal amendment. At a press conference, Mr…

To read the full story

REGULATORY

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Hayate Horiguchi

Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…

By Philip Carrigan

We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…